Nimesulide
 | This article contains promotional content. |
| This article needs attention from an expert on the subject. Please add a reason or a talk parameter to this template to explain the issue with the article. |
 |
| File:Nimesulide2.png | |
| Clinical data | |
|---|---|
| Routes of administration | oral, rectal, topical |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | >97.5% |
| Metabolism | Hepatic |
| Elimination half-life | 1.8-4.7h |
| Excretion | Renal(50%) Fecal(29%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.052.194 |
| Chemical and physical data | |
| Formula | C13H12N2O5S |
| Molar mass | 308.311 |
Nimesulide is a prescription non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties and its approved indications are the treatment of acute pain, the symptomatic treatment of osteoarthrosis and primary dysmenorrhoea in ppadolescent]]s and adults above 12 years old. Nimesulide is among the top 5 non-steroidal anti-inflammatory drugs worldwide.
History
It was launched in Italy for the first time as Aulin and Mesulid in 1985 and is presently available in more than 50 countries worldwide, among others France, Portugal, Greece, Switzerland, Belgium, Ireland, [[Mexico], Brazil.
Availability
It is available in a variety of forms: tablets, powder for dissolution in water, suppositories and topical gel. A recent evaluation from EMEA (the European Medicines Agency) concluded that the overall benefit/risk profile of nimesulide is favourable and in line with that of the other NSAIDs (such as for example, diclofenac, ibuprofen, naproxen).
Trade names
Nimesulide is available through the world as original product with the following trademarks: Aulin, Ainex, Donulide, Edrigyl, Eskaflam, Heugan, Mesulid, Nexen, Nimed, Nimedex, Nisulid, Scaflam, Scaflan. Sulidene and Zolan for veterinary use. Many generic and copy-products also exist (Coxtral, Lusemin, Medicox, Nidol, Nimalox, Nimesil, Nimulid, Ventor, Willgo among others).
Pharmacokinetics
Nimesulide is a very effective and fast acting product on pain and inflammation, with a meaningful experience in real life. As many as almost 480 million patients have been treated with nimesulide from its launch until today. The therapeutic effects of Nimesulide are the result of its complete mode of action which targets a number of key mediators of the inflammatory process such as: COX-2 mediated prostaglandins, free radicals, proteolytic enzymes and histamine. Clinical evidence are available to support a particularly good profile in terms of gastrointestinal tolerability. As all anti-inflammatory drugs, it should be taken in compliance with the recommendations included in the patient leaflet.
External links
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key: underline indicates initially developed first-in-class compound of specific group; #WHO-Essential Medicines; †withdrawn drugs; ‡veterinary use. | |
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |